+1,325.8%
CRWD vs GSK
+64.2%
+1,261.5%
-67.7%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 10y.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.0% | 0.0% | -1.0% | -1.0% |
| 7D | -3.0% | -3.5% | +0.5% | -2.3% |
| 30D | -6.8% | -3.4% | -3.3% | -6.4% |
| 3M | +19.6% | -8.1% | +27.7% | +21.1% |
| 6M | +87.1% | -11.1% | +98.2% | +90.2% |
| YTD | +76.4% | +0.7% | +75.7% | +72.5% |
| 1Y | +90.8% | +20.1% | +70.7% | +77.0% |
| 3Y | +380.0% | +46.1% | +333.9% | +307.0% |
| 5Y | +215.6% | +48.2% | +167.4% | +160.3% |
| All | +1,325.8% | +64.2% | +1,261.5% | +1,027.2% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 10y: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
10y analysis · Full analysis span regression · 6 months rolling